pioglitazone has been researched along with Ischemia in 10 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a nondiabetic murine model of hindlimb ischemia, a single intramuscular injection of pioglitazone-incorporated NP (1 µg/kg) into ischemic muscles significantly improved the blood flow recovery in the ischemic limbs, significantly increasing the number of CD31-positive capillaries and α-smooth muscle actin-positive arterioles." | 7.78 | Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia. ( Egashira, K; Kim-Mitsuyama, S; Matoba, T; Nagahama, R; Nakano, K; Sunagawa, K, 2012) |
| "To observe effects of the drug pioglitazone on expression of hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) in diabetic rats with hindlimb ischemia, and explore the role of pioglitazone in angiogenesis after ischemia and its possible mechanism." | 3.80 | Effect of pioglitazone on expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in ischemic hindlimb of diabetic rats. ( Bai, SJ; Gao, X; Ye, XM; Zhang, J; Zhang, M, 2014) |
| "Pharmacologic delay with pioglitazone can improve extended perforative flap viability through increasing ischemia-induced angiogenesis and choke vessels vasodilation in rat models." | 3.80 | [EFFECT OF PHARMACOLOGIC DELAY WITH PIOGLITAZONE ON EXTENDED PERFORATOR FLAP SURVIVAL IN A RAT MODEL]. ( Chen, S; Gao, W; Li, J; Li, Z; Lin, D; Yan, H, 2014) |
| " In this study, we investigated whether TZDs affect onset, spectral characteristics, and mortality of ischemic ventricular fibrillation (VF) and whether such effects are recapitulated by a non-selective K(ATP) blocker (glyburide) or a mitochondrial K(ATP) blocker (5-hydroxydecanoate)." | 3.78 | Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs. ( Greyson, CR; Lu, L; Reiter, MJ; Sarraf, M; Schwartz, GG; Ye, S, 2012) |
| "In a nondiabetic murine model of hindlimb ischemia, a single intramuscular injection of pioglitazone-incorporated NP (1 µg/kg) into ischemic muscles significantly improved the blood flow recovery in the ischemic limbs, significantly increasing the number of CD31-positive capillaries and α-smooth muscle actin-positive arterioles." | 3.78 | Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia. ( Egashira, K; Kim-Mitsuyama, S; Matoba, T; Nagahama, R; Nakano, K; Sunagawa, K, 2012) |
| "By using a hindlimb ischemia murine model, in this study we have found that pioglitazone restores the blood flow recovery and capillary density in ischemic muscle of diabetic mice and that this process is associated with increased expression of Vascular Endothelial Growth Factor (VEGF)." | 3.75 | Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation. ( Arena, V; Biscetti, F; De Angelis, G; Flex, A; Ghirlanda, G; Iuliano, L; Pecorini, G; Rizzo, P; Stigliano, E; Straface, G, 2009) |
| "Pioglitazone treatment was associated with reductions in limb perfusion at 2 weeks measured by contrast-enhanced ultrasound and Tc(99m)-Sestamibi SPECT-CT." | 1.40 | Pioglitazone inhibits HIF-1α-dependent angiogenesis in rats by paracrine and direct effects on endothelial cells. ( Dromparis, P; McMurtry, MS; Michelakis, ED; Paulin, R; Proctor, S; Sutendra, G, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dromparis, P | 1 |
| Sutendra, G | 1 |
| Paulin, R | 1 |
| Proctor, S | 1 |
| Michelakis, ED | 1 |
| McMurtry, MS | 1 |
| Zhang, M | 1 |
| Gao, X | 1 |
| Bai, SJ | 1 |
| Ye, XM | 1 |
| Zhang, J | 1 |
| Li, Z | 2 |
| Gao, W | 1 |
| Chen, S | 1 |
| Li, J | 1 |
| Yan, H | 1 |
| Lin, D | 1 |
| Biscetti, F | 1 |
| Straface, G | 1 |
| Arena, V | 1 |
| Stigliano, E | 1 |
| Pecorini, G | 1 |
| Rizzo, P | 1 |
| De Angelis, G | 1 |
| Iuliano, L | 1 |
| Ghirlanda, G | 1 |
| Flex, A | 1 |
| Higuchi, A | 1 |
| Ohashi, K | 1 |
| Shibata, R | 1 |
| Sono-Romanelli, S | 1 |
| Walsh, K | 1 |
| Ouchi, N | 1 |
| Sarraf, M | 1 |
| Lu, L | 1 |
| Ye, S | 1 |
| Reiter, MJ | 1 |
| Greyson, CR | 1 |
| Schwartz, GG | 1 |
| Nagahama, R | 1 |
| Matoba, T | 1 |
| Nakano, K | 1 |
| Kim-Mitsuyama, S | 1 |
| Sunagawa, K | 1 |
| Egashira, K | 1 |
| Sheng, CC | 1 |
| Hong, CC | 1 |
| Huang, PH | 1 |
| Sata, M | 1 |
| Nishimatsu, H | 1 |
| Sumi, M | 1 |
| Hirata, Y | 1 |
| Nagai, R | 1 |
| Matsuhashi, N | 1 |
| Watanabe, K | 1 |
| Kanamori, H | 1 |
| Ohnishi, S | 1 |
| Omata, M | 1 |
10 other studies available for pioglitazone and Ischemia
| Article | Year |
|---|---|
Pioglitazone inhibits HIF-1α-dependent angiogenesis in rats by paracrine and direct effects on endothelial cells.
Topics: Angiogenesis Inhibitors; Animals; Cell Line; Endothelial Cells; Hindlimb; Humans; Hypoxia-Inducible | 2014 |
Effect of pioglitazone on expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in ischemic hindlimb of diabetic rats.
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diab | 2014 |
[EFFECT OF PHARMACOLOGIC DELAY WITH PIOGLITAZONE ON EXTENDED PERFORATOR FLAP SURVIVAL IN A RAT MODEL].
Topics: Angiogenesis Inducing Agents; Angiography; Animals; Blood Flow Velocity; Graft Survival; Hypoglycemi | 2014 |
Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation.
Topics: Anilides; Animals; Benzophenones; Blood Flow Velocity; Blood Glucose; Collateral Circulation; Diabet | 2009 |
Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Diabetic Retinopathy; Hypoglycemic Agents; Isch | 2010 |
Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs.
Topics: Animals; Anti-Arrhythmia Agents; Coronary Vessels; Death, Sudden, Cardiac; Decanoic Acids; Female; G | 2012 |
Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia.
Topics: Anilides; Animals; Fibroblast Growth Factor 1; Hindlimb; Humans; Injections, Intramuscular; Ischemia | 2012 |
Mixing of the old with the new: nanoparticle-mediated pioglitazone delivery to enhance therapeutic neovascularization.
Topics: Animals; Hindlimb; Humans; Ischemia; Nanoparticles; Neovascularization, Physiologic; Pioglitazone; P | 2012 |
Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Endothelium, Vascular; Hypoglycemic Agen | 2008 |
PPARgamma agonists for intestinal ischaemia.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; | 2001 |